Published January 1, 2016
| Version v1
Journal article
Open
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
Creators
- 1. IMPPC, Genom & Epigen Canc Predict Program, Campus Can Ruti, Barcelona, Spain
- 2. Hosp Valle De Hebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
- 3. Natl Canc Ctr, Div Genome Biol, Tokyo, Japan
Description
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer with high mortality. One of the MYC family genes, MYC, MYCL or MYCN, is amplified in similar to 20% of the SCLCs; therefore, MYC proteins are potential therapeutic targets in SCLC patients. We investigated the therapeutic impact of Omomyc, a MYC dominant negative, in a panel of SCLC cell lines. Strikingly, Omomyc suppressed the growth of all tested cell lines by inducing cell cycle arrest and/or apoptosis. Induction of G1 arrest by Omomyc was found to be dependent on the activation of CDKN1A, in part, through the TP73 pathway. Our results strongly indicate that SCLC cells carrying amplification of MYC, MYCL or MYCN are addicted to MYC function, suggesting that MYC targeting would be an efficient therapeutic option for SCLC patients.
Files
bib-724016d8-7f3f-46f9-8828-9ffb58b89c2d.txt
Files
(279 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:60c51ceefe24f3c76ff30add2510375a
|
279 Bytes | Preview Download |